Early PQQ supplementation has persistent long-term protective effects on developmental programming of hepatic lipotoxicity and inflammation in obese mice - Jonscher, Karen R; Stewart, Michael S; Alfonso-Garcia, Alba; DeFelice, Brian C; Wang, Xiaoxin X; Luo, Yuhuan; Levi, Moshe; Heerwagen, Margaret J R; Janssen, Rachel C; de la Houssaye, Becky A; Wiitala, Ellen; Florey, Garrett; et al. (The FASEB journal, 2017)
Keywords: Animals; Antioxidants - administration & dosage; Antioxidants - pharmacology; Antioxidants - therapeutic use; Ceramides - metabolism; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 - metabolism; Diet, High-Fat - adverse effects; Dietary Supplements; Female; Interleukin-6 - genetics; Interleukin-6 - metabolism; Liver - drug effects; Liver - metabolism; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II - genetics; Nitric Oxide Synthase Type II - metabolism; NLR Family, Pyrin Domain-Containing 3 Protein - genetics; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity - complications; Obesity - drug therapy; Obesity - etiology; Oxidative Stress; PPAR gamma - metabolism; PQQ Cofactor - administration & dosage; PQQ Cofactor - pharmacology; PQQ Cofactor - therapeutic use; Pregnancy; Prenatal Exposure Delayed Effects - drug therapy; Prenatal Exposure Delayed Effects - etiology; Prenatal Exposure Delayed Effects - prevention & control; CARS; antioxidant; ceramide; PGC-1α; lipidomics